SCHEMBL5141870

SCHEMBL5141870

COc1ccc(O)c(OC)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.45
HIF1A Q16665 1/20 0.44
EPAS1 Q99814 1/20 0.44
TUBB1 Q9H4B7 10/20 0.43
TUBB4A P04350 8/20 0.43
TUBB P07437 8/20 0.43
TUBA3C P0DPH7 8/20 0.43
TUBA1B P68363 8/20 0.43
TUBA4A P68366 8/20 0.43
TUBB4B P68371 8/20 0.43
TUBB3 Q13509 8/20 0.43
TUBB2A Q13885 8/20 0.43
TUBB8 Q3ZCM7 8/20 0.43
TUBA3E Q6PEY2 8/20 0.43
TUBA1A Q71U36 8/20 0.43
TUBA1C Q9BQE3 8/20 0.43
TUBB6 Q9BUF5 8/20 0.43
TUBB2B Q9BVA1 8/20 0.43
MAPT P10636 3/20 0.43
TP53 P04637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29421917 1.00 MAOB (0.45) MAOBHIF1AEPAS1TUBB1TUBB4A
SCHEMBL70459 0.86 ESR1 (0.49) MAOBHIF1AEPAS1TUBB1TUBB4A
Hydrochloric Acid SCHEMBL11424028 0.84 ESR1 (0.47) MAOBHIF1AEPAS1TUBB1TUBB4A
SCHEMBL68271 0.83 TDP1 (0.44) MAOBMAPTTP53CYP3A4CA1
SCHEMBL27423381 0.82 MAPT (0.50) MAOBHIF1AEPAS1TUBB1TUBB4A
Hydrochloric Acid SCHEMBL28767777 0.82 ESR1 (0.46) MAOBHIF1AEPAS1TUBB1TUBB4A
SCHEMBL1402414 0.81 MAPT (0.48) MAOBHIF1AEPAS1TUBB1TUBB4A
SCHEMBL27944716 0.81 PIM1 (0.47) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL9669244 0.80 ALDH1A1 (0.47) MAPTCA1CA2TSHRKDM4E
SCHEMBL29793327 0.80 ACHE (0.52) MAPTCYP3A4CA1CA2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299349-A1 TREATMENT OR PREVENTION OF LEUKAEMIA VESTLANDETS INNOVASJONSSELSKAP AS (NO) 2024-09-12 US disclosed
EP-4021431-A1 TREATMENT OR PREVENTION OF LEUKAEMIA Vestlandets Innovasjonsselskap AS (NO) 2022-07-06 EP disclosed
WO-2021106947-A1 NOVEL QUINONE DERIVATIVE AND ANTITRYPANOSOMAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT 国立大学法人群馬大学 2021-06-03 WO disclosed
WO-2021074614-A1 TREATMENT OR PREVENTION OF LEUKAEMIA VESTLANDETS INNOVASJONSSELSKAP AS (NO) 2021-04-22 WO disclosed
US-8354454-B2 Prodrugs of oxazolidinone CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20110218177-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS MERCK SHARP & DOHME LLC 2011-09-08 US disclosed
WO-2010039474-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-04-08 WO disclosed
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
CN-1181075-C Pyrimidine-4-keto compound, its preparation method and medicine composition containing them ɪά��ʵ���� 2004-12-22 CN disclosed
US-6809099-B2 FOR THERAPY OF CANCER PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2004-10-26 US disclosed
US-20040204419-A1 Saframycins, analogues and uses thereof MYERS ANDREW G (US) 2004-10-14 US disclosed
US-6747032-B2 DOUBLE ALPHA 2/5-HT 2C ANTAGONISTS USED TO TREAT DEPRESSION, IMPULSIVE BEHAVIOUR DISORDERS, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, COGNITIVE DISORDERS AND DISORDERS INVOLVING SEXUAL FUNCTION, SLEEP AND EATING LES LABORATOIRES SERVIER (FR) 2004-06-08 US disclosed
US-20030087916-A1 Pyrimidin-4-one compounds LES LABORATOIRES SERVIER (FR) 2003-05-08 US disclosed
US-20030008873-A1 Saframycins, analogues and uses thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 US disclosed
CN-1381456-A Pyrimidine-4-keto compound, its preparation method and medicine composition containing them SIRVIR LAB (FR) 2002-11-27 CN disclosed
EP-1256583-A1 Pyrimidine-4-one derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2002-11-13 EP disclosed
US-20020082424-A1 Synthesis of CC-1065/duocarmycin analogs THE SCRIPPS RESEARCH INSTITUTE 2002-06-27 US disclosed
US-6310209-B1 INTERMEDIATES INVOLVED IN THE 5-EXO-TRIG RADICAL CYCLIZATION OF AN ARYL HALIDE ONTO A TETHERED VINYL CHLORIDE FORMING THE DIHYDROINDOLE C-RING WITH CHLORINE INSTALLED AS A SUITABLE LEAVING GROUP FOR SUBSEQUENT CYCLOPROPANE SPIROCYCLIZATION. THE SCRIPPS RESEARCH INSTITUTE 2001-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204419-A1 Saframycins, analogues and uses thereof MYC, MAN1B1, MRPS18A MAOB 1047/4885HIF1A 1157/4885EPAS1 4205/4885
US-20110218177-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS CETP, SLCO2B1, OXA1L MAOB 1069/4885HIF1A 568/4885EPAS1 1959/4885
US-20020082424-A1 Synthesis of CC-1065/duocarmycin analogs CBR3, C2CD5, SIRT5 MAOB 1934/4885HIF1A 3739/4885EPAS1 3297/4885
US-20030008873-A1 Saframycins, analogues and uses thereof MYC, MAN1B1, MRPS18A MAOB 1047/4885HIF1A 1157/4885EPAS1 4205/4885
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE NDUFB7, NDUFB1, NDUFB3 MAOB 364/4885HIF1A 2885/4885EPAS1 653/4885
US-20030087916-A1 Pyrimidin-4-one compounds HTR2C, HTR1A, HTR4 MAOB 206/4885HIF1A 535/4885EPAS1 1879/4885
US-20240299349-A1 TREATMENT OR PREVENTION OF LEUKAEMIA BCL9, BCL9L, MCL1 MAOB 2923/4885HIF1A 1886/4885EPAS1 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.